Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience
T Gambichler, S Boms, L Susok… - Journal of the …, 2022 - Wiley Online Library
There is growing evidence that not only the novel coronavirus disease (COVID‐19) but also
the COVID‐19 vaccines can cause a variety of skin reactions. In this review article, we …
the COVID‐19 vaccines can cause a variety of skin reactions. In this review article, we …
[HTML][HTML] Advances in targeting cutaneous melanoma
D Kasakovski, M Skrygan, T Gambichler, L Susok - Cancers, 2021 - mdpi.com
Simple Summary Cutaneous Melanoma (CM), arising from pigment-producing melanocytes
in the skin, is an aggressive cancer with high metastatic potential. While cutaneous …
in the skin, is an aggressive cancer with high metastatic potential. While cutaneous …
[HTML][HTML] Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
…, M Schmalzing, C Sunderkoetter, L Susok… - Annals of the …, 2015 - ard.bmj.com
Background Systemic sclerosis (SSc)-overlap syndromes are a very heterogeneous and
remarkable subgroup of SSc-patients, who present at least two connective tissue diseases (CTD…
remarkable subgroup of SSc-patients, who present at least two connective tissue diseases (CTD…
[HTML][HTML] The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy
L Susok, S Said, D Reinert, R Mansour… - Journal of Cancer …, 2022 - Springer
Purpose To evaluate the pan-immune-inflammation value (PIV) and systemic immune-inflammation
index (SII) in patients with cutaneous melanoma (CM) under immune checkpoint …
index (SII) in patients with cutaneous melanoma (CM) under immune checkpoint …
[HTML][HTML] Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy
…, F Nawroth, A Schüring, L Susok, KM Thoms, L Kiesel… - ESMO open, 2021 - Elsevier
Highlights • Fertility counseling and referral to a specialist in reproductive medicine should
be offered to all patients at fertile age. • In view of the limited preclinical evidence, a fertility-…
be offered to all patients at fertile age. • In view of the limited preclinical evidence, a fertility-…
[HTML][HTML] Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma
Purpose We aimed to determine whether the pan-immune-inflammation value (PIV) of patients
with Merkel cell carcinoma (MCC) at primary diagnosis differs from controls and whether …
with Merkel cell carcinoma (MCC) at primary diagnosis differs from controls and whether …
[HTML][HTML] Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
T Gambichler, S Strutzmann, A Tannapfel, L Susok - BMC cancer, 2017 - Springer
… Lactate dehydrogenase (LDH) and S100B were slightly elevated with 357 U/I (135–225 U/I)
and 0.38 μg/l (cut-off: 0.11 μg/l), respectively. According to the tumour board …
and 0.38 μg/l (cut-off: 0.11 μg/l), respectively. According to the tumour board …
Real‐world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and …
…, K Schatton, T Gambichler, L Susok… - Journal of the …, 2023 - Wiley Online Library
Background Programmed death‐1 (PD‐1) antibodies and BRAF + MEK inhibitors are
widely used for adjuvant therapy of fully resected high‐risk melanoma. Little is known about …
widely used for adjuvant therapy of fully resected high‐risk melanoma. Little is known about …
Decline of programmed death‐1‐positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint …
…, U Schröter, S Höxtermann, L Susok… - British Journal of …, 2020 - academic.oup.com
Background The role of T regulatory lymphocytes (Tregs) and their immunosuppressive
mechanisms in the context of programmed death (PD)‐1 blockade is not completely understood. …
mechanisms in the context of programmed death (PD)‐1 blockade is not completely understood. …
Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients
…, A Kreuter, C Tigges, N Lahner, L Susok… - The Journal of …, 2016 - jrheum.org
Objective. Vasculopathy is a key factor in the pathophysiology of systemic sclerosis (SSc)
and the main cause for Raynaud phenomenon (RP), digital ulcers (DU), and/or pulmonary …
and the main cause for Raynaud phenomenon (RP), digital ulcers (DU), and/or pulmonary …